Hematologic Response to GM-CSF in Current Patients With Acquired PAP and Adults With Normal Hematopoiesis
| First Author (reference no.) . | No. of Patients . | Daily Dose of GM-CSF . | Duration (d) . | Leukocyte Count (×109/L)* . | Neutrophil Count (×109/L)* . | ||
|---|---|---|---|---|---|---|---|
| Mean Peak . | Mean Increment† . | Mean Peak . | Mean Increment† . | ||||
| Individual patient data | |||||||
| Current study | 12‡ | 3.8-5.8 μg/kg [147-229 μg/m2] | 21 | 6.8 ± 1.1 | 0.5 ± 1.1 | 4.3 ± 1.1 | 0.7 ± 0.8 |
| Vadhan-Raj28 | 3 | 120-250 (mean 163) μg/m2 | 14 | 34.1 ± 12.12-153 | 25.0 ± 13.32-153 | 26.4 ± 6.52-153 | 19.8 ± 5.42-153 |
| Lieschke27 | 3 | 3 μg/kg | 10 | 22.6 ± 4.92-153 | 15.3 ± 3.5¶ | 15.4 ± 5.22-153 | 10.1 ± 3.9¶ |
| Haas30 | 7 | 250 μg/m2 | Mean 11.52-155 | 36.6 ± 8.42-153 | 29.7 ± 12.42-153 | 21.2 ± 6.22-153 | 15.8 ± 7.22-153 |
| Berthaud34 | 3 | 250 μg/m2 | 10 | 23.9 ± 5.92-153 | 19.5 ± 5.82-153 | 18.5 ± 5.72-153 | — |
| P value# | <.00001 | <.00001 | <.00001 | <.00001 | |||
| Grouped mean data | |||||||
| Steward29 | 6 | 3 μg/kg | 10 | 41.3 | 31.4 | 31.9 | 24.2 |
| Lord31 | 4 | 150-300 (mean 263) μg/m2 | 10 | 38.0 | 31.0 | 17.1 | 12.1 |
| Vadhan-Raj32 | 3 | 120 μg/m2 | 14 | 19.2 ± 2.1 | — | — | — |
| 3 | 250 μg/m2 | 14 | 42.7 ± 13.0 | — | — | — | |
| Bukowski33 | 4 | 125 μg/m2 | 14 | 21.2 | 14.7 | 16.9 | 11.4 |
| 5 | 250 μg/m2 | 14 | 65.9 | 56.5 | 36.8 | 27.9 | |
| Dale36 | 7 | 250 μg/m2 | 14 | — | — | 14.1 ± 4.5 | 11.9 |
| First Author (reference no.) . | No. of Patients . | Daily Dose of GM-CSF . | Duration (d) . | Leukocyte Count (×109/L)* . | Neutrophil Count (×109/L)* . | ||
|---|---|---|---|---|---|---|---|
| Mean Peak . | Mean Increment† . | Mean Peak . | Mean Increment† . | ||||
| Individual patient data | |||||||
| Current study | 12‡ | 3.8-5.8 μg/kg [147-229 μg/m2] | 21 | 6.8 ± 1.1 | 0.5 ± 1.1 | 4.3 ± 1.1 | 0.7 ± 0.8 |
| Vadhan-Raj28 | 3 | 120-250 (mean 163) μg/m2 | 14 | 34.1 ± 12.12-153 | 25.0 ± 13.32-153 | 26.4 ± 6.52-153 | 19.8 ± 5.42-153 |
| Lieschke27 | 3 | 3 μg/kg | 10 | 22.6 ± 4.92-153 | 15.3 ± 3.5¶ | 15.4 ± 5.22-153 | 10.1 ± 3.9¶ |
| Haas30 | 7 | 250 μg/m2 | Mean 11.52-155 | 36.6 ± 8.42-153 | 29.7 ± 12.42-153 | 21.2 ± 6.22-153 | 15.8 ± 7.22-153 |
| Berthaud34 | 3 | 250 μg/m2 | 10 | 23.9 ± 5.92-153 | 19.5 ± 5.82-153 | 18.5 ± 5.72-153 | — |
| P value# | <.00001 | <.00001 | <.00001 | <.00001 | |||
| Grouped mean data | |||||||
| Steward29 | 6 | 3 μg/kg | 10 | 41.3 | 31.4 | 31.9 | 24.2 |
| Lord31 | 4 | 150-300 (mean 263) μg/m2 | 10 | 38.0 | 31.0 | 17.1 | 12.1 |
| Vadhan-Raj32 | 3 | 120 μg/m2 | 14 | 19.2 ± 2.1 | — | — | — |
| 3 | 250 μg/m2 | 14 | 42.7 ± 13.0 | — | — | — | |
| Bukowski33 | 4 | 125 μg/m2 | 14 | 21.2 | 14.7 | 16.9 | 11.4 |
| 5 | 250 μg/m2 | 14 | 65.9 | 56.5 | 36.8 | 27.9 | |
| Dale36 | 7 | 250 μg/m2 | 14 | — | — | 14.1 ± 4.5 | 11.9 |
*All data are given as the mean ± 1 SD. In some cases, values have been converted from the SEM provided (SD = SEM × √n).
Peak minus baseline count.
Thirteen courses of GM-CSF therapy were administered to 12 patients with acquired PAP; results from the two course of treatment in patient no. 1 are averaged for the overall analysis.
P < .004 for comparison between individual study and current patients using Dunnett’s pairwise comparison test.
¶P ≤ .026 for comparison between individual study and current patients using Dunnett’s pairwise comparison test.
Range of 5 to 22 days GM-CSF administration; patients with marrow infiltrate were excluded from analysis.
#Using ANOVA across all five studies.